Apyx Medical Corp APYX

About Apyx Medical Corp (APYX): stock profile, AI score and financials

Apyx Medical Corp (APYX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores APYX at 27.0/100 on a composite quality score built from its SEC filings, placing it at rank #2,570 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (6.2) and revenue scale (10.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 28.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Apyx Medical Corp reports quarterly revenue of $13.9M, net income of $-3.2M, an operating margin of -13.0%. Top institutional holders of APYX by reported 13-F value include ROYCE & ASSOCIATES, Nantahala Capital Management, Archon Capital Management, based on the most recent SEC filings. APYX trades on the Nasdaq exchange and files with the SEC under CIK 719135. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate APYX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Apyx Medical Corp directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 719135 →